Dexmedetomidine new treatment option for acute agitation in psychiatric disorders
Sublingual dexmedetomidine is a promising treatment for acute agitation in schizophrenia and bipolar disorder, show results from two pivotal phases 3 trials, SERENITY I, and II evaluating BXCL501 (dexmedetomidine; BioXcel Therapeutics).
Currently, dexmedetomidine is available as a solution for intravenous infusion for use in clinical anesthesia and sedation in an intensive care setting. BXCL501, a selective alpha-2a receptor agonist, is an investigational proprietary sublingual thin film of dexmedetomidine.
The multicenter, double-blind, placebo-controlled trials assessed the efficacy and safety of BXCL501 in 381 adults with schizophrenia (SERENITY I) and 378 adults with bipolar disorder (SERENITY II). Patients were randomized in the ratio 1:1:1 to receive either BXCL501 120mcg, 180mcg, or placebo.
The primary endpoint was the absolute change from baseline in acute agitation as measured by the Positive and Negative Syndrome Scale-Excitatory Component ("PEC") score at 2 hours.
Key Results:
· BXCL501 met the primary end point achieving statistically significant and clinically meaningful reductions in the PEC score at 2 hours vs placebo in both the studies.
· In SERENITY I, 67% of patients treated with the 120mcg dose and 87% of patients treated with the 180mcg dose were considered responders (defined as a ≥40% reduction in PEC scores) compared with 34% of patients in the placebo arm.
· In SERENITY II, the response rates were 69% and 85% for the 120mcg and 180mcg doses, respectively, vs 37% for placebo.
· Both studies also met the key secondary end point achieving highly statistically significant improvements in PEC score with BXCL501 at 30 minutes, 45 minutes, 60 minutes and 90 minutes.
· BXCL501 was associated with significant improvements as early as 20 minutes in patients with bipolar disorder at both doses, and as early as 20 minutes in patients with schizophrenia at a dose of 180mcg.
· Additional analysis of BXCL501 using the Agitation and Calmness Evaluation Scale (ACES), and Clinical Global Impression – Improvement Scale (CGI-I) demonstrated statistically significant improvements compared with placebo.
With regard to safety, BXCL501 was found to be well tolerated with all adverse events reported as being mild to moderate in severity.
· The most common adverse events in both studies were somnolence (22% for 180mcg, 21% for 120mcg, 6% for placebo), dry mouth (4.4%, 7.5%, 1.2%, respectively), and dizziness (6.0%, 3.9%, 0.8%, respectively).
The Food and Drug Administration (FDA) previously granted Fast Track designation to BXCL501 for this indication.
BXCL501 is also being investigated for the treatment of agitation associated with dementia in a phase 1b/2 trial (TRANQUILITY), as well as for the treatment of opioid withdrawal symptoms in a phase 1b/2 study.
"These compelling phase 3 results show that BXCL501, if approved, has the potential to become an important new treatment option for patients suffering from acute agitation," wrote the authors.
References:
1) Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia (SERENITY I)
2) Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder (SERENITY II)
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.